ArticlePloS one2025
HPLC-MS profiling and protective potential of the defatted aqueous methanol extract of two Syzygium species against cadmium chloride-induced nephrotoxicity in rats.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Anti-psoriatic potential of nanocarrier formulated with Deverra tortuosa DC. and Deverra triradiata hochst aerial extracts: in vivo evaluation in mice.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Modulation of NF-κB and cytokine signaling byFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadmium (Cd), a highly toxic heavy metal, is used in food and agricultural products while displaying nephrotoxicity to animals and humans. The genus Syzygium (Myrtle family) is rich in precious phenolic metabolites with various therapeutic values. This study investigated the phenolic content and the therapeutic potential of the defatted 80% aqueous methanol extract (DE) of S. malaccense and S. samarangense leaves against Cd-induced kidney injury in rats for the first time. High-performance liquid chromatography-Mass spectrometry (HPLC-MS), in addition to Folin-Ciocalteu and aluminium chloride colourimetric methods, depicted the phenolic metabolites, total phenolic content, and total flavonoid content, respectively. The nephroprotective effect was investigated using fifty-six female Sprague Dawley rats divided into eight groups: control group, CdCl2-treated group (3 mg/kg/i.p/7 days), and three groups of each species treated with the DE (250, 500, and 1000 mg/kg/o.p., respectively). The phytochemical analysis revealed the richness of S. samarangense DE by phenolic and flavonoid content over S. malaccense. The HPLC-MS showed the tentative identification of sixty-two compounds, in positive and negative ionization modes, belonging to phenolic acids (1-6), flavonoids (7-52), and miscellaneous compounds (53-62). Both extracts were considered safe up to 5 g/kg. At the maximum tested dose (100 mg/Kg), the DEs significantly (p < 0.001) boosted the levels of antioxidant markers by 3.3-6 fold, lessened the inflammatory indicators by 66.8%-75.1%, and reduced the apoptotic parameters by 45.4-73.3%, compared to the CdCl2-treated group. Additionally, the DEs maintained the mitochondrial function and inhibited autophagy via decreasing adenosine monophosphate-activated protein kinase by 49.2%-50.6%, and baclin-1 by 49.5%-56.1%. Additionally, the DEs increased the mammalian target of rapamycin (mTOR) by 4.7-4.9 fold. Additionally, the DE ameliorated CdCl2-induced elevations in serum ALT and AST, indicating a protective effect against systemic toxicity. Ultimately, the DE of S. malaccense and S. samarangense protect against Cd-induced nephrotoxicity that may be correlated to their abundant phenolic content. However, selecting suitable formulations and implementing clinical studies are among the future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.